Paper Details

  1. Home
  2. Paper Details

Capmatinib Triggers Responses in NSCLC.

Author:

NewsMedia reports that provide information on the latest events and information. Newspapers, television, and the Internet are the main media.

Overview

Capmatinib, a MET inhibitor, was effective in treating patients with advanced non-small cell lung cancer (NSCLC). The response rate was higher in treatment-naïve patients than in previously treated patients.
Paper Details　
Original Abstract of the Article :
A phase II trial of the MET inhibitor capmatinib found that 72% of treatment-naïve patients responded to the drug, whereas the ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1158/2159-8290.CD-NB2018-148

データ提供：米国国立医学図書館（NLM）

Capmatinib: A New Hope for NSCLC Patients

This research explores the potential of capmatinib, a MET inhibitor, as a treatment option for non-small cell lung cancer (NSCLC). The study utilizes [methodology] to evaluate the effectiveness of [treatment] in [research subject] . The findings suggest that [treatment] is [benefit] for [research subject] .

Targeting MET for Lung Cancer Treatment

The study highlights the potential of MET inhibition as a promising therapeutic strategy for NSCLC. The findings suggest that [treatment] can [benefit] . This research underscores the need for [benefit] for [research subject] .

Navigating the Complexities of Lung Cancer Treatment

This research emphasizes the importance of developing targeted therapies to address the diverse needs of lung cancer patients. The study's findings suggest that [treatment] can [benefit] . This research is [benefit] for [research subject] .

Dr.Camel's Conclusion

This study presents compelling evidence for the efficacy of capmatinib in treating NSCLC. The findings highlight the promise of MET inhibition as a targeted therapeutic approach, offering hope for individuals battling this challenging disease. As Dr. Camel always says, "Just like a camel can withstand the harsh desert environment, researchers must be resilient in their pursuit of effective treatments for lung cancer."
Date :
  1. Date Completed n.d.
  2. Date Revised 2019-11-20
Further Info :

Pubmed ID

30429129

DOI: Digital Object Identifier

10.1158/2159-8290.CD-NB2018-148

Related Literature

Article Analysis
・Side Effects of capmatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.